Conclusion: The RISCAVID study highlights the difficulty of controlling bone mineral metabolism in HD patients and lends support to the hypothesis that a carefully chosen phosphate binder might impact survival in HD patients.
PMID: 20349412 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)